Objectives. This study sought to assess the long-term clinical consequences of reocclusion after coronary thrombolysis.
surgery and with a patent infarct-related artery at coronary angiography within 48 h after thrombolysis were enrolled in the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT) trial. At a mean (-+SD) of 77 -+ 23 days after thrombolysis, 248 patients (87%) underwent follow-up angiograpby. Reocclusion was observed in 71 (29%) of 248 patients. To compare outcome between 71 patients with and 177 without reocclusion an analysis of event-free survival, defined as a clinical course without death, reinfarction and revascularization, was performed.
Results. Over a 3-year follow-up period, event-free survival was significantly better in patients without reocclusion: At 1 year it was 63% for patients with and 83% for those without reoeclusion (p < 0.001). In the first year, two or more cardiac-related events occurred in 24% of patients with and 6% of those without reocclusion (p < 0.001). Patients with reocclusion had a markedly higher reinfarction and revascnlarization rate. At 1 year the reinfarction rate was 23% for patients with and 5% for those without reocclusion (p < 0.001).
Conclusions. This analysis shows the adverse influence of reocclusion on long-term clinical outcome in relation to reinfarction and need for revascularization. To further optimize prognosis after thrombolysis, prevention of reocclusion should become a main priority. Future research should focus on the criteria and timing of elective revascularization procedures in the prevention of coronary reocclusion.
(J Am Coil Cardiol 1995; 26:1440-4) In the past decade, thrombolytic therapy has become the cornerstone of treatment for acute transmural myocardial infarction. In 80% of all treated patients, recanalization of the infarct-related artery is eventually achieved (1) . However, several studies (2) (3) (4) (5) (6) (7) (8) have demonstrated that reocclusion occurs in 5% to 30% of patients after successful thrombolysis. Reocclusion has proved to be associated with an adverse short-term clinical outcome (3) and impaired residual left ventricular function (3, 9) , the most important prognostic factor after myocardial infarction after thrombolysis (10) . The benefit of thrombolytic therapy--improvement of both short-and long-term survival--could therefore be optimized by the prevention of reocclusion. Routine invasive strategies after thrombolysis have not been shown to improve clinical outcome (11) .
There have been several studies (28) specifically addressing coronary reocclusion and the intermediate-term effects of oral antithrombotic therapy on reocclusion. These studies may provide insight into the long-term effects of reocclusion after coronary thrombolysis.
Several trials (12) (13) (14) have been conducted to determine long-term survival after thrombolytic therapy. To our knowledge, this report is the first follow-up study to assess the effects of reocclusion on long-term clinical outcome. The data are derived from the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT) trial (2) .
Methods
Study protocol. A detailed description of the APRICOT study protocol and criteria used to select patients has previously been published (2) . In brief, 300 patients -<70 years old with no history of coronary surgery were enrolled between August 15, 1987 and June 30, 1991 . They presented with chest pain lasting >30 rain and <4 h combined with a minimum of 0.2 mV of ST segment elevation in two contiguous electrocardiographic (ECG) leads. They received thrombolytic therapy with either streptokinase or anistreplase followed by a fixed dose of intravenous heparin (20,000 U/24 h). Downward dose adjustments were made only when the activated partial thromboplastin time exceeded 2.5 times baseline values. Standard coronary care treatment was given (15) . Within 48 h after the November 15, 1995: start of thrombolytic treatment, coronary angiography showed grade 1 to 3 stenosis of the infarct-related artery according to the criteria defined by the European Cooperative Study Group (16) . European Cooperative Study Group grades 1 to 3 are identical to Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow. Sixteen patients were retrospectively judged to have an occluded infarct-related artery and were not included in the study (Fig. 1 ). All 284 patients with a patent infarct-related artery were randomized to treatment with 325 mg of aspirin daily, coumadin (international normalized ratio 2.8 to 4.0) or placebo. Infarct-related artery status at 3 months was the primary end point of the APRICOT trial. Revascularization was performed for clinical reasons only. Thirty-six patients did not undergo follow-up angiography because of refusal (n -28), coronary bypass surgery (n = 6) or death (n = 2) ( Fig. 1 ). Reocclusion was defined as a grade 4 to 5 stenosis (16) and corresponds to TIMI flow grades 0 to 2. The culprit lesions of patients undergoing angioplasty before the scheduled second angiography were analyzed in the catheterization laboratory immediately before the angioplasty procedure. On the basis of results of the second angiography, two groups of patients were defined: 1) 71 patients with reocclusion; and 2) 177 without reocclusion.
Follow-up. Patients that participated in the APRICOT trial were screened for cardiac-related events over a 3-year followup period. Medical files were used to study hospital admissions for the following reasons: coronary angioplasty, coronary bypass surgery and reinfarction. In addition, survival status of all enrolled patients was assessed. Municipal registries and telephone contact with the patient, general practitioner or relatives enabled us to complete missing information.
Clinical end points. Outcome between groups was compared according to vessel status at the second angiography, and clinical information since the day of randomization was used. The primary end point of the analysis was event-free survival. An event-free follow-up was defined as a clinical course without death, reinfarction or readmission for coronary angio-plasty or coronary bypass surgery. Criteria for recurrent myocardial infarction were chest pain accompanied by typical ECG changes combined with an increase in creatine kinase levels higher than twice the upper normal limit.
Statistics. Baseline characteristics are expressed as mean value +_ SD and were compared by the Student t test. Whenever appropriate, the chi-square test was used for other comparisons between groups. Event-free survival curves were obtained as described by Kaplan and Meier (17) . To determine the statistical significance of the difference between curves, the log-rank test was used. A p value <0.05 was considered statistically significant.
Results
Follow-up. Of the 284 patients participating in the APRICOT trial, 248 (87%) had a second coronary angiography performed a mean of 77 _+ 23 days after thrombolysis ( Fig.  1 ). Patients without angiographic foUow-up more often had a history of myocardial infarction (17% vs. 6%, p < 0.025), were slightly older (60 _+ 7 vs. 56 + 9 years, p < 0.01) and were more often female (31% vs. 17%, p < 0.05) (2) . The 248 patients with both a first and second angiography formed the present study group. Follow-up data were collected for a median of 31 months (25th to 75th percentile, 19 to 46 months) starting on the day of randomization. No patient was lost to follow-up. In the first follow-up year six patients died. Information on 238 (98%) of the surviving 242 patients after >1 year of follow-up was available. Table 1 shows the baseline characteristics of patients with and without reocclusion. No statistical differences were observed.
Clinical outcome. Figure 2 shows event-free survival in patients with and without reocclusion over a 3-year follow-up period. In the reocclusion group, the majority of all events occurred in the first 3 months. In this short period of time, the event-free survival rate decreased to 68% for patients with reocclusion compared with 92% for those without reocclusion. There was a significant (p < 0.001) overall difference in the event-free survival curves, with most of the difference occurring within the first weeks. At 1 year these percentages were 63% and 83%, respectively (p < 0.001). Reinfarction rates at this stage were 23% and 5%, respectively (p < 0.001).
Over the entire follow-up period, 19 patients (27%) with and 16 patients (9%) without reocclusion had a reinfarction. Reinfarction occurred in the same area as the index infarction, except in one patient. Proportionally, the reocclusion group experienced three times as many reinfarctions ( Table 2 ). Data are expressed as event counts rather than event rates because of the decreasing follow-up percentage after the first year of follow-up.
In the first year of follow-up the incidence of cardiacrelated events was 59% for patients with and 24% for those without reocclusion (p < 0.001). These rates were similar over 3 years: 75% for the former and 33% for the latter. Patients without reocclusion experienced 39 cardiac-related events in the first year of follow-up. Forty-four percent of events occurred within 3 months after randomization, in contrast to 74% of all observed events in patients with reocclusion (p < 0.03).
At 1 year of follow-up, a clinical course with two or more cardiac-related events was seen in 24% of patients with compared with 6% of patients without reocclusion (p < 0.001). Over the entire follow-up period, multiple events occurred in 22 patients (31%) with and 15 patients (9%) without reocclusion.
Discussion
Reoeelusion and event-free survival. To our knowledge, this is the first study to demonstrate the sustained adverse influence of reocclusion on clinical outcome. The first months after successful thrombolysis appear to be of major importance: -60% of all cardiac-related events in the reocclusion group occurred within 3 months after thrombolytic therapy. Although the mortality rate was low, a result of the study design (2), there was a marked difference in event-free survival in favor of patients without reocclusion, due to the relatively high rate of reinfarction and angioplasty in patients with reocclusion.
Long-term survival after myocardial infarction is primarily predicted by the functional status of the left ventricle (18) . Reocclusion is associated with impaired recovery of left ventricular function (3, 9) . These findings strongly suggest that mortality would have been higher if selection criteria had not been as strict as in the present study. The 1-year mortality rate for the study group was 2.4%. Even over a 3-year follow-up period, only 12 (5%) of 248 patients died. Three-year survival rates reported by long-term survival trials of thrombolysis vary from 84% to 87% (12, 14) . Because of the low mortality profile, the difference in event-free survival might even be slightly underestimated.
Reoeelusion and reinfarction. Reinfarction occurs more frequently in patients with than without reocclusion. Our data are in accordance with earlier findings (3) showing that most symptomatic recurrent ischemic events occur within the first days after thrombolytic therapy. The majority of the reocclusions (78%) are not associated with clinically apparent reinfarction. During this period and thereafter, reocclusion is likely to occur asymptomatically because of the development of collateral channels (19) .
Only two of the 15 reinfarctions observed in the first 3 months did not occur within 10 days. Overall, 84% of the reinfarctions in the reocclusion group occurred within 3 months after enrollment. In contrast, only 20% of the reinfarctions in patients without reocclusion occurred in the 3-month period. Therefore, in this group, 80% of the reinfarctions occurred later in the first year and in the second and third follow-up year. These reinfarctions are most likely to be related to the ongoing atherosclerotic process, whereas the early reinfarctions most likely result from rethrombosis after thrombolytic therapy (12) .
Reoeclusion and need for revaseularization. Over the entire follow-up period, revascularizations represented the majority of cardiac-related events. It should be noted that these procedures were performed for clinical, not angiographic, reasons only. In the reocclusion group, -50% of all angioplasty procedures were performed before the second angiography. The information obtained at angiographic follow-up November 15, 1995 November 15, :1440 LONG-TERM FOLLOW-UP OF REOCCLUSION may have caused the physician to perform more revascularizations than usual. However, the consequences for the pattern of the event-free survival curves are negligible because the period leading up to the second angiography is of greater clinical importance.
Reocclusion and multiple events. Reocclusion has proved to be associated with a higher incidence of cardiac-related events and hospital admissions. Only 15 (9%) of the 177 patients without reocclusion had two or more events compared with 22 (31%) of 71 with reocclusion. Therefore, nearly 33% of patients with reocclusion experienced multiple events. This finding, combined with the fact that 37 patients with reocclusion had no events, indicates that some patients with reocclusion have a higher risk for a complicated clinical course than others.
Effects of thrombolytic therapy on long-term improvement. The results of the present study emphasize the clinical importance of an initially and persistently patent infarct-related artery comparison with an initially open but reoccluded artery. An earlier long-term analysis (20) of the prognostic effects of patency included only one angiographic observation performed 1 month after thrombolysis and also identified patency as an important prognostic factor, which proved to be independent of left ventricular function.
To optimize the results of thrombolytic therapy, a combination of two approaches might be successful.
1. The reocclusion rate should be reduced as much as possible. New antithrombotic drugs, such as hirudin and hirulog (6, 21) , may better prevent reocclusion. Identification of patients with a high risk for reocclusion would also be of major importance. So far, clinical variables have failed to determine predictors of reocclusion (22) .
2. Patients with reocclusion might benefit from elective angioplasty within a few weeks after myocardial infarction, when coronary angioplasty can safely be performed, especially if collateral supply is sufficient. Late recanalization may prevent ventricular dilation (23, 24) . This ventricular enlargement is a compensatory mechanism to restore stroke volume at the expense of an increased preload and afterload to the left ventricle, which may stimulate further dilation (9, 25) . It has been demonstrated that ventricular enlargement occurs more frequently with an occluded than with a patent infarct-related artery (9, 26, 27) and that reperfusion can prevent dilation (28) .
One could argue whether all patients of the reocclusion group would have benefited from a recanalization procedure. More than 50% of patients with reocclusion had no events over a 3-year follow-up period; however, asymptomatic reocclusion might have occurred in some of them. An option would be to perform coronary angioplasty in a prespecified subgroup. Our data show that new cardiac-related events are most likely to occur in patients with an event in the first 3 months. Twentytwo new events occurred after angiographic follow-up: 11 occurred in patients who had already had 1 event.
In the APRICOT trial (2), a conservative strategy was intended: Revascularizations were performed only for reasons of recurrent ischemia not responsive to medical anti-ischemic treatment. The advantage of elective angioplasty would be that ventricular enlargement would be less extensive than with angioplasty performed at the time of symptoms. These options should be investigated further, because the optimal benefits of thrombolytic therapy have not yet been attained.
Study limitations. One limitation of the present study design is that only those patients who survived the acute phase and, in addition, were fit enough to undergo catheterization within 48 h, were eligible to enter the study. Furthermore, only patients who had a patent infarct-related artery at first angiography and underwent follow-up angiography were included in this analysis. This selection bias certainly contributed to the low mortality rate observed and may have influenced the number of observed events. Another restriction concerns the exclusion of patients with coronary bypass surgery before the second angiography. Finally, only patients <-70 years of age participated in the trial, which may also have contributed to an underesti-mation of the incidence of cardiac-related events after successful thrombolysis.
Despite the aforementioned restrictions, the number of revascularizations might have been lower if a second angiography had not been performed. Generally, symptoms of recurrent ischemia not responding to anti-ischemic treatment would be an indication to perform revascularization. In the present trial, the information obtained at follow-up angiography may have led the physician to follow a less conservative treatment strategy.
Conclusions. The results of the present study demonstrate that reocclusion after successful thrombolysis for acute myocardial infarction is associated with a less favorable long-term clinical course. Reocclusion results in a relatively high rate of reinfarction and angioplasty procedures during the first 3 months, drastically affecting event-free survival. The observed effect on clinical outcome remains significant over a 3-year follow-up period. These findings underscore that both the prevention and, possibly, adequate treatment of reocclusion should become the main priorities of thrombolytic therapy for myocardial infarction. Future research might focus on the timing, criteria and results of elective revascularization procedures.
